Thoroughbred Financial Services’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.34M | Buy |
21,227
+1,421
| +7% | +$306K | 0.26% | 87 |
|
|
2026
Q1 | $4.31M | Sell |
19,806
-11
| -0.1% | -$2.44K | 0.26% | 85 |
|
|
2025
Q4 | $4.53M | Buy |
19,817
+311
| +2% | +$70.8K | 0.27% | 74 |
|
|
2025
Q3 | $4.52M | Buy |
19,506
+769
| +4% | +$157K | 0.28% | 75 |
|
|
2025
Q2 | $3.48M | Sell |
18,737
-3,697
| -16% | -$687K | 0.24% | 88 |
|
|
2025
Q1 | $4.7M | Buy |
22,434
+624
| +3% | +$121K | 0.29% | 68 |
|
|
2024
Q4 | $3.88M | Sell |
21,810
-186
| -0.8% | -$34.2K | 0.24% | 80 |
|
|
2024
Q3 | $4.34M | Sell |
21,996
-675
| -3% | -$126K | 0.28% | 70 |
|
|
2024
Q2 | $3.89M | Sell |
22,671
-3,340
| -13% | -$553K | 0.26% | 81 |
|
|
2024
Q1 | $4.74M | Sell |
26,011
-594
| -2% | -$102K | 0.46% | 52 |
|
|
2023
Q4 | $4.12M | Buy |
26,605
+3,098
| +13% | +$452K | 0.33% | 63 |
|
|
2023
Q3 | $3.5M | Buy |
23,507
+3,684
| +19% | +$541K | 0.34% | 63 |
|
|
2023
Q2 | $2.67M | Buy |
19,823
+281
| +1% | +$41.2K | 0.35% | 70 |
|
|
2023
Q1 | $3.11M | Sell |
19,542
-188
| -1% | -$28.7K | 0.46% | 55 |
|
|
2022
Q4 | $3.19M | Buy |
19,730
+171
| +0.9% | +$26.2K | 0.52% | 50 |
|
|
2022
Q3 | $2.63M | Buy |
19,559
+188
| +1% | +$27K | 0.5% | 46 |
|
|
2022
Q2 | $2.97M | Buy |
19,371
+38
| +0.2% | +$5.81K | 0.55% | 42 |
|
|
2022
Q1 | $3.13M | Buy |
19,333
+2,420
| +14% | +$352K | 0.51% | 46 |
|
|
2021
Q4 | $2.29M | Buy |
16,913
+919
| +6% | +$109K | 0.48% | 42 |
|
|
2021
Q3 | $1.73M | Buy |
15,994
+373
| +2% | +$42.6K | 0.42% | 55 |
|
|
2021
Q2 | $1.76M | Buy |
15,621
+539
| +4% | +$60.7K | 0.44% | 54 |
|
|
2021
Q1 | $1.63M | Buy |
15,082
+1,879
| +14% | +$201K | 0.45% | 54 |
|
|
2020
Q4 | $1.41M | Buy |
13,203
+1,146
| +10% | +$110K | 0.44% | 53 |
|
|
2020
Q3 | $1.06M | Buy |
12,057
+94
| +0.8% | +$8.85K | 0.4% | 62 |
|
|
2020
Q2 | $1.18M | Sell |
11,963
-1,247
| -9% | -$110K | 0.49% | 56 |
|
|
2020
Q1 | $1.01M | Buy |
13,210
+195
| +1% | +$16.6K | 0.36% | 86 |
|
|
2019
Q4 | $1.15M | Sell |
13,015
-730
| -5% | -$60.6K | 0.38% | 80 |
|
|
2019
Q3 | $1.04M | Sell |
13,745
-150
| -1% | -$10.3K | 0.39% | 79 |
|
|
2019
Q2 | $1.01M | Buy |
13,895
+873
| +7% | +$68.6K | 0.38% | 74 |
|
|
2019
Q1 | $1.05M | Buy |
13,022
+546
| +4% | +$44.7K | 0.43% | 67 |
|
|
2018
Q4 | $1.15M | Buy |
+12,476
| New | +$1.1M | 0.56% | 50 |
|
Other funds holding ABBV
Thoroughbred Financial Services's ABBV Position: Q2 2026 in Review
Thoroughbred Financial Services increased its AbbVie (ABBV) stake by 7.2% in Q2 2026, buying an estimated $306K and bringing the position to 21,227 shares worth $5.34M. The position accounts for 0.26% of the portfolio, ranked #87.
Thoroughbred Financial Services first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Thoroughbred Financial Services held 21,227 shares of AbbVie worth $5.34M as of Q2 2026.
- Thoroughbred Financial Services bought 1,421 AbbVie shares in Q2 2026, an estimated $306K.
- AbbVie made up 0.26% of Thoroughbred Financial Services's portfolio in Q2 2026, its #87 holding.
- Thoroughbred Financial Services first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Thoroughbred Financial Services's 13F filing for Q2 2026, filed 11 Aug 2026.